All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Sara Ghorashian, University College London, London, UK. We asked, What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

The COVID-19 pandemic has had an impact on the logistics of the already complex delivery of chimeric antigen receptor (CAR) T-cell therapies, by delaying both clinical studies and CAR T-cell accreditation for many centers. Ghorashian provides an overview of the challenges faced and dimensions to consider for the future, including vaccination, complications, and disease context.

Share: